Clinical trial
Treatment of Major Depressive Disorder With Psychotic Features.
NCT00174590 · Rush University Medical Center, Other · Terminated
Key facts
| NCT number | NCT00174590 |
|---|---|
| Title | Treatment of Major Depressive Disorder With Psychotic Features. |
| Official title | Treatment of Major Depressive Disorder With Psychotic Features With Risperidone Monotherapy; Risperidone and Sertraline; or Haloperidol and Sertraline |
| Lead sponsor | Rush University Medical Center, Other |
| Collaborators | Janssen, LP Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Major Depression With Psychotic Features |
| Intervention type | Drug |
| Interventions | risperidone |
| Enrollment | 30 |
| Start date | Sep 1, 2001 |
| Completion | Aug 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | Jan 10, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: